Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Phase 2

Completed

• Conditions: Solitary Fibrous Tumors
• Interventions: Drug: Trabectedin; Drug: Adriamycin; Drug: Dacarbazine

• Registration Number: NCT03023124
• Lead Sponsor: Italian Sarcoma Group

Brief Summary

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

Detailed Description

Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or doxorubicin plus dacarbazine.

In case of progression or unacceptable toxicity while under the experimental treatment prior to the completion of the 6 cycles, the patients will be offered to cross to the other arm (trabectedin arm to doxorubicin plus dacarbazine arm and vice versa).

Study Timeline

• Study First Submitted: 2016-12-19
• Study First Submitted QC: 2017-01-13
• Study First Posted: 2017-01-18
• Study Start: 2018-03-04
• Status Verified: 2024-02
• Primary Completion: 2024-12-06
• Study Completion: 2024-12-06
• Last Update Submitted: 2024-12-06
• Last Update Posted: 2024-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

1. The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.
2. Age ≥18 years
3. Histological centrally and molecularly confirmed diagnosis of solitary fibrous tumor (inclusive of the last available tumor sample)
4. Locally advanced disease (i.e. surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or feasible, or easier, after cytoreduction) and/or metastatic disease
5. Measurable or evaluable disease with RECIST
6. Evidence of progression by RECIST during the 6 months before study entry
7. Patients must be cytotoxic chemotherapy naïve (patients treated with neoadjuvant/adjuvant chemotherapy cannot be included) or could have received a previous target agent in front-line setting.
8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
9. Adequate bone marrow function
10. Adequate organ function
11. Cardiac ejection fraction ≥50% as measured by echocardiogram
12. Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study.
13. No history of arterial and/or venous thromboembolic event within the previous 12 months.

Exclusion Criteria

1. Any prior treatment with cytotoxic chemotherapy
2. >1 line of anticancer targeted agents
3. Previous treatment with any other investigational or not investigational agents within 14 days of first day of study drug dosing
4. Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered
5. Previous radiotherapy to 25 % of the bone marrow
6. Major surgery within 4 weeks prior to study entry
7. Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
8. Pregnancy or breast feeding
9. Cardiovascular diseases resulting in a New York Heart Association Functional Status >2 (24). Medical history of a myocardial infarction < 6 months prior to initiation of study treatment
10. Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
11. Known history of human immunodeficiency virus infection
12. Active or chronic hepatitis B or C requiring treatment with antiviral therapy
13. Medical history of hemorrhage or a bleeding event ≥ Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment
14. Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
15. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
16. Expected non-compliance to medical regimens

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Trabectedin	Trabectedin	trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
Adriamycin and Dacarbazine	Adriamycin	Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
Adriamycin and Dacarbazine	Dacarbazine	Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles

Primary Outcome Measures

Name	Time	Method
Overall Tumor Response Rate	From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first assessed up to 54 weeks.	evaluate the activity of trabectedin and of adriamycin in combination with dacarbazine, according to Response Evaluation Criteria in Solid Tumor (RECIST), version 1.1

Secondary Outcome Measures

Name	Time	Method
Choi Response Rate	week 6, week 12, week 18, then every 12 weeks up to 54 weeks	Percentage of patient who experienced Complete or Partial Responses after treatment according to Choi Criteria.
Overall Survival (OS)	From enrollment up to 5 years	Time from the date of enrollment to date of death
Progression Free Survival (PFS)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks	Survival free of progressive disease evaluated from enrollment up to progression according to RECIST, or death
Clinical Benefit Rate (CBR)	week 6, week 12, week 18, then every 12 weeks up to 54 weeks	Percentage of patients who have achieved complete response, partial response or stable disease ≥ 6 months
Response rate by RECIST after the cross over	week 18, week 24, week 30, week 36 and then every 12 weeks up to 54 weeks	Percentage of patient who experienced Complete or Partial Responses according RECIST 1.1 after cross over
Progression Free Survival (PFS) after cross over up to progression according to RECIST, or death	From date of cross over until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks	Survival free of progressive disease evaluated from
Safety according to Common Terminology Criteria for Adverse Events (CTCAE)	From enrollment every 3 weeks up to 54 weeks	Safety profile of the treatment evaluated according to Common Terminology Criteria for Adverse Events version 4.03

Trial Locations

Locations (6)

Nuovo Ospedale di Prato; 🇮🇹 Prato, Firenze, Italy

Policlinico Universitario Campus Biomedico; 🇮🇹 Roma, RM, Italy

IRCCS Istituto ortopedico Rizzoli; 🇮🇹 Bologna, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori; 🇮🇹 Milano, MI, Italy

Ospedale Giaccone; 🇮🇹 Palermo, Italy

Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -; 🇮🇹 Candiolo, Italy